RE

REPLIGEN CLINICAL PARTNERS LP

  • CIK: 0000885434
  • EIN: 04-3140576
  • Business address: 117 FOURTH AVE, NEEDHAM, Massachusetts, 02194

Information

  • Mailing address
    REPLIGEN CLINICAL PARTNERS LP, 117 FOURTH AVE, NEEDHAM, Delaware, 02194
  • Phone
    6174499560
  • State location
    Massachusetts
  • State of incorporation
    Delaware
  • Fiscal year end
    December 31
  • SIC
    2833 - (CF Office: Office of Life Sciences) MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
  • Filings
    N/A

About REPLIGEN CLINICAL PARTNERS LP

REPLIGEN CLINICAL PARTNERS LP (CIK: 0000885434) is an American company incorporated in the state of Massachusetts. Head office is located at 117 FOURTH AVE, NEEDHAM, Massachusetts, 02194. Work in the industry 2833 - (CF Office: Office of Life Sciences) MEDICINAL CHEMICALS & BOTANICAL PRODUCTS. REPLIGEN CLINICAL PARTNERS LP is a public company and trade via Over-The-Counter (OTC).

Ownership

Updating!

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by REPLIGEN CLINICAL PARTNERS LP

Filings Format Description Filed/Effective File/Film Number
REVOKED Document Acc-no: 9999999997-13-014145 (34 Act) Size: 61 KB Oct-28-2009

000-21700

131100972
DEFA14A Document

Additional definitive proxy solicitation materials

Acc-no: 0000889697-00-000068 ( Act) Size: 8 KB		 Apr-04-2000

000-21700

593046
DEFS14A Document Acc-no: 0000889697-00-000028 ( Act) Size: 140 KB Feb-15-2000

000-21700

546196
PRE 14A Document

Preliminary proxy statement not related to a contested matter or merger/acquisition

Acc-no: 0000950103-00-000180 ( Act) Size: 142 KB		 Feb-08-2000

000-21700

527033
PRE 14A Document

Preliminary proxy statement not related to a contested matter or merger/acquisition

Acc-no: 0000950103-99-001072 ( Act) Size: 139 KB		 Dec-13-1999

000-21700

99773112
10-K405 Document Acc-no: 0000950103-97-000597 ( Act) Size: 111 KB Oct-09-1997

000-21700

97693138
10-K405 Document Acc-no: 0000950103-97-000208 ( Act) Size: 110 KB Apr-07-1997

000-21700

97575816

Recent 20 filings. View all REPLIGEN CLINICAL PARTNERS LP filings

Reviews

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Frequently Asked Questions

Tags:

  • REPLIGEN CLINICAL PARTNERS LP overview
  • REPLIGEN CLINICAL PARTNERS LP job
  • REPLIGEN CLINICAL PARTNERS LP stock
  • REPLIGEN CLINICAL PARTNERS LP ownership
  • REPLIGEN CLINICAL PARTNERS LP CEO
  • REPLIGEN CLINICAL PARTNERS LP documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

Cordyceps Sunshine Biotech Holdings Co., Ltd.
Update: Jan 21, 2023
PSLY.COM, Inc.
Update: Aug 29, 2022
Jushi Holdings Inc.
Update: Aug 29, 2022
ZACHARY VENTURES INC
Update: Aug 25, 2022
WEIKANG BIO-TECHNOLOGY GROUP CO., INC.
Update: Aug 25, 2022
VITAQUEST INTERNATIONAL INC
Update: Aug 24, 2022

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 4658 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 1507 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 1988 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 2503 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 4609 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 3909 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 2913 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 3208 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 3126 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by